NEWS
Kronos Bio Announces First Patient Dosed with KB-0742 in an Expansion Cohort Focused on Platinum-Resistant High-Grade Serous Ovarian Cancer
Kronos Bio (NASDAQ: KRON) has dosed the first patient in an expansion cohort of its KB-0742 clinical trial, focusing on platinum-resistant high-grade serous ovarian cancer (HGSOC). The trial uses an 80mg dose on a four-days-on, three-days-off schedule, which cleared the dose escalation phase. This dosing regimen is expected to provide a 1.8-fold increase in AUC compared to the previous 60mg three-days-on, four-days-off schedule.
KB-0742 has shown a favorable safety profile in over 100 patients, with no grade 3 or 4 neutropenia observed. The company plans to provide an efficacy update on this expansion cohort in the first half of 2025. HGSOC is particularly sensitive to CDK9 inhibition due to MYC amplification or overexpression and homologous recombination deficiencies, affecting a significant portion of ovarian cancer patients.
KB-0742 has shown a favorable safety profile in over 100 patients, with no grade 3 or 4 neutropenia observed. The company plans to provide an efficacy update on this expansion cohort in the first half of 2025. HGSOC is particularly sensitive to CDK9 inhibition due to MYC amplification or overexpression and homologous recombination deficiencies, affecting a significant portion of ovarian cancer patients.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1097Followers
69Following
7612Visitors
Follow